Fisher Asset Management LLC Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE)

Fisher Asset Management LLC cut its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 17.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 711,436 shares of the medical instruments supplier's stock after selling 151,184 shares during the period. Fisher Asset Management LLC owned 1.40% of Haemonetics worth $60,835,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of HAE. Westfield Capital Management Co. LP boosted its holdings in Haemonetics by 37.0% in the 3rd quarter. Westfield Capital Management Co. LP now owns 559,963 shares of the medical instruments supplier's stock worth $50,161,000 after buying an additional 151,144 shares during the period. Victory Capital Management Inc. lifted its stake in Haemonetics by 50.0% in the 3rd quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier's stock worth $32,007,000 after purchasing an additional 119,072 shares in the last quarter. Kingdon Capital Management L.L.C. purchased a new stake in Haemonetics in the 3rd quarter worth approximately $9,952,000. Lisanti Capital Growth LLC purchased a new stake in Haemonetics in the 3rd quarter worth approximately $7,025,000. Finally, California Public Employees Retirement System lifted its stake in Haemonetics by 36.9% in the 4th quarter. California Public Employees Retirement System now owns 229,717 shares of the medical instruments supplier's stock worth $19,643,000 after purchasing an additional 61,935 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HAE shares. Barrington Research reiterated an "outperform" rating and issued a $105.00 target price on shares of Haemonetics in a research note on Friday, April 12th. TheStreet cut shares of Haemonetics from a "b-" rating to a "c+" rating in a research report on Thursday, February 29th. Finally, StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd.

Haemonetics Trading Up 1.1 %

NYSE:HAE traded up $1.07 during trading hours on Friday, reaching $94.40. The company's stock had a trading volume of 368,663 shares, compared to its average volume of 429,361. The firm has a market capitalization of $4.79 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 2.20 and a beta of 0.34. The firm has a 50-day simple moving average of $82.36 and a 200-day simple moving average of $82.72. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $95.26. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company's revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.85 EPS. Research analysts expect that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.